- Home
- BROS vs CDTX Comparison
BROS vs CDTX Comparison
Compare BROS & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BROS | CDTX |
|---|---|---|
| Founded | 1992 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 6.9B |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BROS | CDTX |
|---|---|---|
| Price | $64.02 | $220.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 12 |
| Target Price | $77.16 | ★ $128.75 |
| AVG Volume (30 Days) | ★ 2.7M | 947.6K |
| Earning Date | 02-11-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.73 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $1,537,335,000.00 | N/A |
| Revenue This Year | $28.88 | N/A |
| Revenue Next Year | $25.56 | N/A |
| P/E Ratio | $126.52 | ★ N/A |
| Revenue Growth | ★ 28.93 | N/A |
| 52 Week Low | $47.16 | $15.22 |
| 52 Week High | $86.88 | $221.20 |
Technical Indicators
Market Signals| Indicator | BROS | CDTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.48 | 85.79 |
| Support Level | $62.25 | $219.91 |
| Resistance Level | $64.25 | $221.00 |
| Average True Range (ATR) | 1.73 | 0.54 |
| MACD | 0.17 | -3.90 |
| Stochastic Oscillator | 77.05 | 87.86 |
Price Performance
Historical ComparisonAbout BROS Dutch Bros Inc.
Dutch Bros Inc is an operator and franchisor of drive-thru coffee shops that are focused on serving hand-crafted beverages. The company's hand-crafted beverage-focused lineup features hot and cold espresso-based beverages, cold brew coffee products, proprietary energy drinks, tea, lemonade, smoothies and other beverages. The company has two reportable operating segments Company-operated shops and Franchising. It derives maximum revenue from Company operated shops.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.